Italy's Azimut buys Chigago-based North Square Investments in $165 mln deal
Azimut, which is carrying out the deal through its U.S. arm Azimut US Holdings, said it would pay $60 million at closing and a further $50 million over the following four years.
The price tag could reach $160 million when including earn-out mechanisms and management incentives, it said, adding it would pay partly in cash and partly through shares in Milan-listed Azimut Holding.
Azimut said it would contribute its 51% stake in Kennedy Capital Management as part of the deal and combine the Missouri-based asset manager, which has $4.5 billion in assets under management (AUMs), with NSI to create a player with around $20 billion in AUMs.
The transaction cements the role of the U.S. market as Azimut's second biggest after Italy with a total of consolidated pro-forma AUMs of $50 billion.
Azimut estimated the deal would increase its recurring 2024 net profit, calculated without the contribution from the TNB (The New Bank) spin-off, by around 5% within the first 12 months.
NSI plans to launch seven active exchange traded funds for U.S. retail investors during the first year, Azimut said.
Azimut is buying 100% of NSI, which originated through a hiving off of assets from Oak Ridge Investments, from private equity firm Estancia Capital Partners and other shareholders.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
14 minutes ago
- Reuters
HEDGE FLOW Hedge funds ditch tech and buy essentials, Goldman Sachs says
LONDON, July 28 (Reuters) - Hedge funds fled technology stocks at the fastest pace in 12 months in the latest week, just as the S&P 500 (.SPX), opens new tab reached all-time highs, a note to Goldman Sachs (GS.N), opens new tab clients and seen by Reuters said. The S&P 500, which includes seven tech stocks in its top 10 largest constituents by market value, has surged roughly 28% since its 2025 low, while the Nasdaq Composite (.IXIC), opens new tab has jumped 38% in that time. As of Friday, the S&P 500's forward price to earnings ratio, which reflects the value of a company's stock relative to its projected future earnings, was 23.11, around five-month highs, according to LSEG/Datastream. "U.S. equities valuations (such as price earnings ratios) are now 30% higher than their recent decade average, while 10-year yields remain stubbornly high and volatile. The future path of equities may depend partly on a decline in long-term rates; however, we do not seem to be there yet," Lombard Odier Investment Managers head of macro Florian Ielpo said in a note on Friday. Globally, hedge funds sold tech stocks, some of the most richly valued equities, more than any other sector last week, the Goldman Sachs note said. Rather than shorting the sector, hedge funds tended to ditch long bets and exit trades, the bank said. A short bet is designed to profit from a drop in an asset price. This week's exodus was the largest the bank had seen since July 2024, Goldman Sachs said. Hedge funds fleeing tech stocks centered on trading in North America and Europe. Every kind of tech stock was sold, including semiconductor chip companies, as well as those in software and IT services, the bank said. Meanwhile, shares in consumer staples - companies that sell items that people purchase regardless of economic conditions - were among the most net bought U.S. stock sectors this week, Goldman said. Hedge funds piled into these stocks for the fourth straight week and their trades were almost entirely long positions - those that will profit if the stock prices rise. The kind of companies whose shares hedge funds bought included those that sell food and beverages and personal care products.
Reuters
16 minutes ago
- Reuters
European leaders react to US-EU trade deal
July 28 (Reuters) - The U.S. struck a framework trade agreement with the European Union on Sunday, imposing a 15% import tariff on most EU goods and averting a bigger trade war between the two allies that account for almost a third of global trade. Following are reactions from European leaders to the deal. "It is a sombre day when an alliance of free peoples, brought together to affirm their common values and to defend their common interests, resigns itself to submission." "This is not an agreement ... Donald Trump ate von der Leyen for breakfast, this is what happened and we suspected this would happen as the U.S. president is a heavyweight when it comes to negotiations while Madame President is featherweight." "This agreement has succeeded in averting a trade conflict that would have hit the export-orientated German economy hard. This applies in particular to the automotive industry, where the current tariffs of 27.5% will be almost halved to 15%." "I consider it positive that there is an agreement, but if I don't see the details I am not able to judge it in the best way." "The agreement brings much-needed predictability to the global economy and Finnish companies. Work must continue to dismantle trade barriers. Only free transatlantic trade benefits both sides the most." "This agreement does not make anyone richer, but it may be the least bad alternative. What appears to be positive for Sweden, based on an initial assessment, is that the agreement creates some predictability." "A deal provides a measure of much needed certainty for Irish, European and American businesses who together represent the most integrated trading relationship in the world. While Ireland regrets that the baseline tariff of 15% is included in the agreement, it is important that we now have more certainty on the foundations for the EU-US trade relationship, which is essential for jobs, growth and investment."
Reuters
20 minutes ago
- Reuters
Nordic Capital, Permira make $3 billion offer for vaccine maker Bavarian Nordic
July 28 (Reuters) - A consortium led by Nordic Capital and Permira has made an around $3 billion offer to buy all shares in Bavarian Nordic ( opens new tab, the vaccine maker said on Monday. Innosera, a newly formed company controlled by the consortium, will make an offer of 233 Danish crowns per Bavarian Nordic share. The Danish company is recommending the offer to its shareholders. The offer price marks a premium of 21% compared to the stock's closing price last Wednesday and values the deal at about 19 billion crowns ($2.98 billion), Bavarian said in a statement. Shares of Bavarian, which specializes in vaccines for mpox, smallpox and other infectious diseases, had gained 21% since Thursday when it confirmed it was in talks with Nordic Capital and Permira over a potential bid. They opened 2% higher on Monday at 238 crowns per share. Kempen analysts said in a research note that the offer price came below their 300 crown target price, but the premium was fair considering uncertain U.S. market conditions and the fact Bavarian relies mostly on its contract-based public-preparedness business. Bavarian is a key supplier to governments globally, including public health preparedness programmes in the United States. The deal will be subject to customary conditions, including that Innosera needs to own or have valid acceptances for more than 90% of Bavarian Nordic's voting rights and shares at the end of the offer period, the group said. Danish pension fund ATP, which holds a 10% stake in Bavarian according to LSEG data, told Reuters that it had no interest in accepting the offer. "Neither the timing nor the price of the presented offer reflects the opportunities we see in the company," Claus Berner Møller, vice president for Danish Equities at ATP, said in an emailed statement. Upon completion of the offer, expected in the fourth quarter of 2025, the consortium intends to delist Bavarian Nordic's shares from Nasdaq Copenhagen. ($1 = 6.3711 Danish crowns)
